Lovasa will eat both the lunch of both Vascepa and Generic Vascepa. Without patients, doctors, and insurers understanding the real health benefits of Vascepa they will gravitate to what they see as the least costly option which is generic Lovasa. Sad that the FDA has no interest in correcting this. I say sell us to BP and if that were Pfizer, they might have the political clout with the FDA to get them to find a resolution beneficial to Pfizer.